Dermata Therapeutics, Inc. Warrant
Symbol: DRMAW (NASDAQ)
Company Description:
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
- Today's Open: $0.0212
- Today's High: $0.0212
- Today's Low: $0.0169
- Today's Volume: 20.92K
- Yesterday Close: $0.0212
- Yesterday High: $0.0212
- Yesterday Low: $0.0174
- Yesterday Volume: 2.99K
- Last Min Volume: 4.65K
- Last Min High: $0.0169
- Last Min Low: $0.0169
- Last Min VWAP: $0.0169
- Name: Dermata Therapeutics, Inc. Warrant
- Website: https://www.dermatarx.com
- Listed Date: 2021-08-13
- Location: SAN DIEGO, CA
- Market Status: Active
- CIK Number: 0001853816
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $
- Round Lot: 100
- Outstanding Shares:
- Asset Type: WARRANT
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-17 | 8-K | View |
| 2025-09-10 | 8-K | View |
| 2025-08-25 | 8-K | View |
| 2025-08-14 | SCHEDULE 13G | View |
| 2025-08-13 | 10-Q | View |
| 2025-08-13 | 8-K | View |
| 2025-07-30 | 8-K | View |
| 2025-07-16 | 8-K | View |
| 2025-07-07 | 8-K | View |
| 2025-06-05 | 8-K | View |
| 2025-06-02 | ARS | View |
| 2025-06-02 | DEFA14A | View |
| 2025-06-02 | DEF 14A | View |
| 2025-05-23 | PRE 14A | View |
| 2025-05-21 | 8-K | View |
| 2025-05-16 | 8-K | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-14 | 8-K | View |
| 2025-05-14 | 10-Q | View |
| 2025-05-09 | SCHEDULE 13G/A | View |